Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-11-14

FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

FDA approved a supplemental application for EMEND (aprepitant) from Merck Sharp & Dohme LLC to expand its approved use as an antiemetic for prevention of chemot…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EMEND (aprepitant)

Snippet

SUPPL AP for EMEND (APREPITANT)